Hypothesis\nWe propose that senescence-associated PAI-1 secreted by glomerular endothelial cells activates integrin αvβ3 on proximal tubular epithelial cells, triggering focal adhesion kinase (FAK)-Src signaling and nuclear translocation of YAP/TAZ, which drives p16INK4a transcription independent of DNA damage. This mechanotransductive loop converts glomerular endothelial senescence into tubular epithelial senescence, propagating nephron loss and GFR decline.\n\n## Mechanistic Rationale\n- Endothelial senescence precedes podocyte loss and elevates PAI-1, a known modulator of integrin signaling [1].\n- PAI-1 can bind vitronectin and engage integrin αvβ3, activating FAK-Src and the Hippo effectors YAP/TAZ [2], pathways that have been shown to regulate p16INK4a expression in fibroblasts and epithelial cells.\n- Tubular p16INK4a up‑regulation drives G1 arrest and a SASP rich in IL-1β, IL-6, TNF-α, amplifying inflammation and fibrosis [2].\n- Current data show correlated increases of p16 and p21 with age but do not test whether blocking the endothelial‑to‑tubular signal interrupts the senescence cascade [3].\n\nThus, integrin αvβ3 serves as a mechanistic bridge that translates glomerular endothelial SASP into a cell‑autonomous tubular senescence program.\n\n## Testable Predictions\n1. In aged mice, pharmacological inhibition of integrin αvβ3 (e.g., with cilengitide) will reduce tubular p16INK4a-positive cells without altering glomerular endothelial PAI-1 levels.\n2. Genetic deletion of integrin αvβ3 specifically in proximal tubular epithelial cells will attenuate age‑related tubular SASP, interstitial fibrosis, and preserve GFR compared with littermate controls.\n3. Exogenous PAI‑1 applied to cultured human kidney tubuloids will increase YAP/TAZ nuclear localization and p16INK4a expression; this effect will be blocked by integrin αvβ3 knockdown or FAK inhibition.\n4. Combining integrin αvβ3 inhibition with a senolytic (e.g., FOXO4‑DRI) will yield additive preservation of renal function in aged mice, exceeding the benefit of either intervention alone.\n\n## Experimental Approach\n- In vivo: Use aged (18‑month) C57BL/6 mice treated with cilengitide or tubular‑specific Itgav‑Cre;Itgb3^fl/fl knockouts. Measure glomerular PAI‑1 (immunostaining), tubular p16INK4a/p21, YAP/TAZ localization (confocal), serum creatinine/BUN, and GFR (FITC‑sinistrin clearance) at 3‑ and 6‑month intervals. Assess fibrosis (Masson’s trichrome) and tubular atrophy.\n- In vitro: Differentiate human iPSC‑derived proximal tubular epithelial cells in transwell culture. Add recombinant PAI‑1 (± cilengitide, FAK inhibitor PF‑573228, or YAP inhibitor verteporfin). Quantify nuclear YAP/TAZ (Western blot of fractionation), p16INK4a mRNA (qPCR), and SASP cytokines (ELISA). Use siRNA against ITGAV or ITGB3 to confirm specificity.\n- Validation in human tissue: Correlate glomerular endothelial PAI‑1 expression with tubular p16INK4a and phosphorylated FAK in biopsy samples from young vs. older donors (n≥30) using multiplex immunohistochemistry.\n\nIf integrin αvβ3 blockade fails to reduce tubular p16INK4a or improve GFR, the hypothesis would be falsified, prompting search for alternative mediators (e.g., TGF‑β, endothelin‑1) linking glomerular and tubular senescence.